Shanghai Pharmaceuticals Holding (601607.SH): The listing application for Lacosamide API has been approved.

31/10/2023

GMT Eight

Announcement: Shanghai Pharmaceuticals Holding (601607.SH) announced that its wholly-owned subsidiary Shangyao Kangli (Changzhou) Pharmaceuticals Co., Ltd. ("Shangyao Kangli") has received the "Chemical Raw Material Drug Market Application Approval Notice" (Notice No.: 2023YS00679) issued by the State Drug Administration ("National Drug Administration") for its drug Lakaosha'an. The drug has been approved for production.

Baimtec Material (688563.SH) released its performance for the first three quarters, with a net profit of 503 million yuan, a year-on-year increase of 25.02%.

Shenzhen Chipscreen Biosciences (688321.SH): CS32582 capsules have been granted approval for Phase I clinical trials for the treatment of psoriasis.

Contact: contact@gmteight.com

Shanghai Pharmaceuticals Holding (601607.SH): The listing application for Lacosamide API has been approved.

RECOMMEND

US Stock Market Move | FuboTV (FUBO.US) rose more than 6% after reaching a merger agreement with the streaming services owned by Walt Disney Company (DIS.US) before.

US Stock Market Move | Income decreased in Q4 after adjustment, and Freeport-McMoRan Copper & Gold (FCX.US) fell more than 5%.

US Stock Market Move | Bank stocks rise across the board, Bank of America Corp (BAC.US) up 1.9%